PMCID: PMC7489598
Join at Timestamps 0:00 Intro 1:52 Q1: What happens when you stop a GLP-1 5:33 Lifestyle-only comparators: DPP, Look AHEAD, POUNDS Lost 8:15 Austin on the cessation conversation 1 2:41 BMJ 2026: weight and cardiometabolic regression 17:59 The statin framing 23:41 Austin: first 6 months off GLP-1 28:07 Q2: Osteopenia and heavy lifting 35:28 LIFTMOR protocol 38:00 Outro Next Steps For evidence-based resistance training programs: barbellmedicine.com/training-programs For individualized training consultation: barbellmedicine.com/coaching Explore our full library of articles on health and performance: barbellmedicine.com/resources To consult with Drs
Optic Labs supplies BPC-157 strictly as a research chemical for in vitro and preclinical laboratory research not for human consumption, clinical use or any therapeutic application
This activation attenuates angiotensin II (Ang II)driven cardiac remodelingevidenced by downregulated expression of hypertrophic markers (ANP, BNP, and -MHC), improved systolic function in transverse aortic constriction (TAC) mice (increased ejection fraction [EF%] and fractional shortening [FS%], alongside reduced left ventricular internal diameter [LVID] and heart weight-to-body weight ratio [HW/BW]), and suppression of fibrotic progression (decreased expression of Col1a1, Col3a1, fibronectin, and -smooth muscle actin [-SMA])
In burn and wound models, it sped up closure and improved granulation tissue
code cart flumazenil multiple dose vial